Supernus Pharmaceuticals (SUPN) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research note published on Friday morning.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

A number of other brokerages have also commented on SUPN. Stifel Nicolaus lowered shares of Supernus Pharmaceuticals from a buy rating to a hold rating and set a $47.00 price objective on the stock. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reissued a hold rating and set a $41.00 price objective on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. FBR & Co initiated coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a buy rating and a $53.00 price objective on the stock. Cantor Fitzgerald reissued a buy rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Finally, ValuEngine lowered shares of Supernus Pharmaceuticals from a buy rating to a hold rating in a report on Friday, December 1st. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Supernus Pharmaceuticals presently has an average rating of Buy and an average target price of $49.90.

Shares of Supernus Pharmaceuticals (SUPN) traded down $0.60 during trading hours on Friday, reaching $44.15. 468,765 shares of the company’s stock were exchanged, compared to its average volume of 449,375. Supernus Pharmaceuticals has a 12-month low of $23.10 and a 12-month high of $50.04. The company has a market cap of $2,293.98, a price-to-earnings ratio of 41.65 and a beta of 1.18.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The business’s quarterly revenue was up 41.5% on a year-over-year basis. analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.

In other news, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Victor Vaughn sold 55,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total transaction of $2,206,050.00. The disclosure for this sale can be found here. Insiders sold a total of 120,000 shares of company stock worth $5,014,650 in the last ninety days. Insiders own 6.70% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Supernus Pharmaceuticals by 0.5% in the 2nd quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock valued at $289,962,000 after purchasing an additional 31,331 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after acquiring an additional 984,200 shares during the period. State Street Corp raised its position in shares of Supernus Pharmaceuticals by 3.1% in the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock valued at $60,230,000 after acquiring an additional 42,165 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Supernus Pharmaceuticals by 10.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock valued at $54,654,000 after acquiring an additional 122,042 shares during the period. Finally, Neumeier Poma Investment Counsel LLC raised its position in shares of Supernus Pharmaceuticals by 1.6% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock valued at $38,391,000 after acquiring an additional 14,430 shares during the period. 98.22% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/13/supernus-pharmaceuticals-supn-downgraded-by-zacks-investment-research-to-hold.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply